ReviewDrug design, development and therapy2026
Roles of Goserelin in Gynecological Disorders.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Goserelin is a gonadotropin-releasing hormone (GnRH) agonist with a long history of clinical application and well-established efficacy and safety profile. Its mechanism of action centers on sustained GnRH receptor desensitization, leading to pituitary downregulation, ovarian suppression, and reduction of estradiol and progesterone to postmenopausal levels; this forms the basis for its efficacy in hormone-dependent gynecological conditions. Over the past three decades, the use of goserelin has been expanded to an increasing number of indications and clinical scenarios. Approved gynecological indications of goserelin include endometriosis, uterine fibroids, usage as an agent for endometrial thinning, and usage as an agent for ovarian downregulation prior to assisted reproduction. More recent research continues to explore the use of goserelin in gynecological diseases such as adenomyosis and different types of female cancers. Goserelin may also be a useful tool in clinical scenarios where gynecologic management is required as part of multi-disciplinary therapy. This review consolidates the established and emerging roles of goserelin across the broad spectrum of benign and malignant gynecological conditions, underscoring its remarkable clinical versatility and the breadth of evidence that support its continued expansion of utility in contemporary practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.